Regeneron Pharmaceuticals Inc (REGN)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	19,479,200	18,634,800	16,923,000	16,909,200	15,884,100	15,428,600	15,529,900	14,306,000	14,014,900	13,775,400	13,337,600	10,055,100	9,779,100	9,097,600	7,860,200	8,644,100	7,689,100	7,109,100	6,651,000	6,928,600
Total current liabilities	US$ in thousands	3,423,400	3,598,600	3,104,400	3,100,100	3,141,300	2,879,200	3,033,900	3,007,600	3,932,500	3,714,800	3,732,400	3,217,800	2,697,400	2,337,800	3,702,400	2,055,200	2,096,600	1,765,400	1,713,100	1,511,400
Current ratio		5.69	5.18	5.45	5.45	5.06	5.36	5.12	4.76	3.56	3.71	3.57	3.12	3.63	3.89	2.12	4.21	3.67	4.03	3.88	4.58

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $19,479,200K ÷ $3,423,400K
= 5.69

The current ratio of Regeneron Pharmaceuticals, Inc. has displayed relatively stable and strong performance over the past eight quarters. The average current ratio over this period is 5.30, indicating that the company has a solid ability to meet its short-term obligations using its current assets. The current ratio consistently remains above 5, reflecting a healthy liquidity position and a capability to cover its current liabilities more than five times over. This indicates that Regeneron Pharmaceuticals has a prudent approach to managing its short-term financial obligations.